Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs IAC/Interactivecorp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.97 (market cap $29.60B), while IAC/Interactivecorp trades at $40.81 (market cap $2.97B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 10× IAC/Interactivecorp's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PPLI | |
|---|---|---|
Market Cap | $29.60B | $2.97B |
Sector | Health | Media |
52-Week High | $491.22 | $47.62 |
52-Week Low | $205.48 | $31.52 |
Enterprise Value | $27.56B | $3.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
PPLI trades at $40.88, up 0.54% with bearish technical signals but strong analyst support. The stock shows mixed fundamentals with Q2 2026 earnings beat of $6.77 EPS versus -$0.40 expected, though revenue declined to $2.39B in 2025. Valuation metrics appear attractive with P/E of 6.76 and P/B of 0.59. Recent news highlights digital growth and MGM investment gains driving profitability.
Investment outlook balances deep value against operational challenges. The 69% buy rating and $60.50 price target suggest 48% upside, but negative cash flow and volatile earnings pose risks. Key catalysts include asset monetization and MGM stake value realization, while execution risks and debt levels require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
